gatifloxacin has been researched along with Cerebral Nocardiosis in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin was injected subcutaneously at 100 mg/kg body weight every 8 h for 4 weeks." | 1.35 | In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis. ( Daw-Garza, A; Lozano-Garza, HG; Ocampo-Candiani, J; Rocha, NC; Said-Fernández, S; Vera-Cabrera, L; Waksman de Torres, N; Welsh, O, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daw-Garza, A | 1 |
| Welsh, O | 1 |
| Said-Fernández, S | 1 |
| Lozano-Garza, HG | 1 |
| Waksman de Torres, N | 1 |
| Rocha, NC | 1 |
| Ocampo-Candiani, J | 1 |
| Vera-Cabrera, L | 1 |
| Mittal, V | 1 |
| Fernandes, M | 1 |
2 other studies available for gatifloxacin and Cerebral Nocardiosis
| Article | Year |
|---|---|
In vivo therapeutic effect of gatifloxacin on BALB/c mice infected with Nocardia brasiliensis.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Fluoroquinolones; Gatifl | 2008 |
Cotrimoxazole-resistant Nocardia sclerokeratitis: effective therapy with fourth-generation fluoroquinolones.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resi | 2012 |